GeneDx is trading approximately 10.5% up at $75.00 in pre-market trading today after reporting a return to adjusted profitability and a second-quarter revenue beat.
- Revenue for Q2 2026 reached $114.4 million, an 11% year-over-year increase that surpassed analyst expectations.
- The company achieved a small adjusted profit of $0.4 million, driven by strong growth in exome and genome testing volumes.
- Management reaffirmed its full-year 2026 revenue guidance of $475–$490 million following a previous guidance cut.